Results from the OCEANIC-STROKE trial show that the investigational Factor XIa inhibitor, asundexian, not only reduces the recurrent ischaemic stroke risk, but when they do occur, they are less likely to be disabling or fatal.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/factor-xia-inhibition-tied-benefit-beyond-stroke-prevention-2026a1000ewf?src=rss
Author :
Publish date : 2026-05-08 15:59:00
Copyright for syndicated content belongs to the linked Source.
